NL-OMON26160招募中不适用
Treatment with add-on IVIG in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvemEnt
Prinses Beatrix spierfonds, Sanquin Plasma Products0 个研究点目标入组 48 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Adult patients (18-80 years) with idiopathic inflammatory myopathy (IIM), according to diagnostic criteria:
- •- Dermatomyositis
- •- Non-specific/overlap myositis including antisynthetase syndrome; formerly known as polymyositis
- •- Immune mediated necrotizing myopathy
- •Disease duration < 12 months
- •Minimal disability defined as at least 10% loss on Manual Muscle Testing (MMT) and abnormal scores on two other Core Set Measures (CSMs) of the international Myositis Assessment and Clinical Studies (IMACS) group (see ‘Primary and secondary outcomes’).
- •Signed informed consent
排除标准
- •A potentially eligible patient who meets any of the following criteria will be excluded from participation in this study:
- •Disease duration > 12 months
- •Immunosuppressive medication or immunomodulatory treatment within the last 3 months (e.g. azathioprine, methotrexate, mycophenolate mofetil, tacrolimus, cyclophosphamide, ciclosporine, IVIg, biologicals, Janus kinase inhibitors, plasmapheresis).
- •Severe muscle weakness (i.e. bedridden, severe dysphagia, or respiratory muscle weakness) necessitating more intensive treatment than standard glucocorticoids.
- •Exceptions to abovementioned exclusion criteria:
- •Prior use of steroids will be carefully judged by the treating physician. Patients are eligible for inclusion if there is no clinical evident response to prior treatment with:
- •High-dosed steroids, such as dexamethasone or intravenous methylprednisolone (e.g. 1000mg daily for three days) within 1 week prior to inclusion.
- •Daily dosed prednisone 1mg/kg, or equivalent, used for up to 2 weeks prior to screening visit.
- •Treatment with low dose prednisone up to three months before screening.
- •Use of biologicals or other immunosuppressive or immunomodulatory treatment when meeting the following criteria:
- •- Stable dose for the past 6 months
- •- The biological has been approved for a non-muscular condition (e.g. hematological condition, eczema) and is not known for its use in idiopathic inflammatory myopathy
- •- No history of biological-induced inflammatory myopathy
- •Related to IVIG:
- •- History of thrombotic episodes within 10 years prior to enrolment
- •- Known allergic reactions or other severe reactions to any blood-derived product
- •- Known IgA deficiency and IgA serum antibodies
- •- Pregnancy (wish)
- •- Use of loop diuretics
- •- Use of nephrotoxic medication
- •Conditions that are likely to interfere with:
- •- Compliance (legal incompetent and/or incapacitated patients are excluded), or,
- •- Evaluation of efficacy (e.g. due to severe pre-existing disability as a result of any other disease than myositis or due to language barrier)
研究者
相似试验
招募中
2 期
Add-on Intravenous Immunoglobulins in Early MyositisInflammatory Myopathy, IdiopathicImmune-Mediated Necrotizing MyopathyPolymyositisMyositisDermatomyositisAntisynthetase SyndromeNCT05832034Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)48
进行中（未招募）
1 期
Early treatment with intravenous immunoglobulins for newly diagnosed myositis patientsEUCTR2016-004766-26-NLAcademic Medical Center20
已完成
2 期
Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies (IMMEDIATE): a pilot study.myositisNL-OMON46904Academisch Medisch Centrum20
已完成
不适用
IMMEDIATE study- idiopathic inflammatory myopathies- myositis (practical/clinical synonym)- auto-immune disease- neuromuscular diseaseNL-OMON25293Department of Neurology, Academic Medical Center Amsterdam20
尚未招募
4 期
Efficacy of Myo-inositol in PCOS patientsCTRI/2024/06/068972Amrita Institute Of Medical Science